Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification
FI: 7,786
Type: Article
Collaboration
Year: 2017
Writers
Sepulveda-Sanchez, JM; Vaz, MA; Balana, C; Gil-Gil, M; Reynes, G; Gallego, OR; Martinez-Garcia, M; Vincent, E; Quindos, M; Luke, R; Ramos, A; Ruano, Y; Perez-Segura, P; Benavides, M; Sanchez-Gomez, P; Hernandez-Lain, A.
Magazine
Title: NEURO-ONCOLOGY
Quartile
- D1